Noble Financial Initiates Coverage on Vical Inc. (VICL) with a Buy
More News related to VICL
- Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
- Vical Added to NASDAQ Biotechnology Index
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
- Vical (VICL) Misses Q3 EPS by 1c; Revenues Above Consensus
Noble Financial initiates coverage on Vical Inc. (Nasdaq: VICL) with a Buy.
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Related Categories
New CoverageStocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
